Enamine was founded in 1991 with the advent of high throughput screening in early drug discovery. The driving force of the company’s development was the rapidly increasing demand for new chemical compounds. Over the past 20 years, Enamine has become a global provider of Screening Compounds, Building Blocks, and Fragments for supporting a wide range of research programs conducted by pharmaceutical and biotech companies, drug discovery centres, academic institutions and other research organizations worldwide.